Literature DB >> 32587331

Limited usefulness of resting hemodynamic assessments in predicting exercise capacity in hypertensive patients.

Małgorzata Kurpaska1, Paweł Krzesiński2, Grzegorz Gielerak2, Beata Uziębło-Życzkowska2.   

Abstract

Reliable assessments of reduced exercise capacity based on resting tests are one of the major challenges in clinical practice. The aim of this study was to evaluate the relationship between hemodynamic parameters obtained via resting tests (echocardiography and impedance cardiography (ICG)) and objective parameters of exercise capacity assessed via cardiopulmonary exercise testing and exercise ICG in patients with controlled arterial hypertension (AH). The left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), diastolic function parameters (e', E/A, E/e'), cardiac output (CO), stroke volume (SV), and systemic vascular resistance index were evaluated for any correlations with selected parameters of exercise capacity, such as peak oxygen uptake (VO2) and peak CO in 93 people with AH (mean age 54 years, 47 women). Statistically relevant correlations occurred between indices of exercise capacity (peak VO2; peak CO) and only the following hemodynamic parameters: diastolic blood pressure (R = 0.23, p = 0.026; R = 0.24, p = 0.021; respectively), e' (R = 0.32, p = 0.002; R = 0.24, p = 0.027), E/e' (R = 0.35, p < 0.001; ns), E/A (R = 0.23, p = 0.030; R = 0.21, p = 0.047), SV at rest (ns; R = 0.24, p = 0.019), and CO at rest (ns; R = 0.21, borderline p = 0.052). No significant correlations between the exercise capacity parameters and either LVEF or GLS were observed. No hemodynamic parameter proved to be an independent correlate of either peak VO2 or peak CO. The association between hemodynamic parameters at rest and parameters of exercise capacity was weak and limited to selected parameters of diastolic function. Exercise capacity assessment in patients with AH based on resting tests alone is insufficiently reliable and should be supplemented with exercise tests.
© 2020. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2020        PMID: 32587331     DOI: 10.1038/s41371-020-0373-x

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  5 in total

1.  Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.

Authors:  Mevlüt Koç; Abdi Bozkurt; Durmus Yildiray-Sahin; Ilker Unal; Esmeray Acartürk
Journal:  Cardiol J       Date:  2009       Impact factor: 2.737

Review 2.  Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE)†.

Authors:  Thomas H Marwick; Thierry C Gillebert; Gerard Aurigemma; Julio Chirinos; Genevieve Derumeaux; Maurizio Galderisi; John Gottdiener; Brian Haluska; Elizabeth Ofili; Patrick Segers; Roxy Senior; Robyn J Tapp; Jose L Zamorano
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2015-06       Impact factor: 6.875

3.  Haemodynamic parameters in postmenopausal women - beneficial effect of moderate continuous exercise training.

Authors:  Andrzej Molisz; Zelia Schmederer; Janusz Siebert; Tahane Kadamani; Paulina Glasner; Katarzyna Rosłonkiewicz; Katarzyna Nowicka-Sauer; Piotr Gutknecht; Bartosz Trzeciak; Andrzej Suchanowski
Journal:  Ann Agric Environ Med       Date:  2019-02-20       Impact factor: 1.447

Review 4.  Echocardiographic Diastolic Stress Testing: What Does It Add?

Authors:  Kyung-Hee Kim; Garvan C Kane; Christina L Luong; Jae K Oh
Journal:  Curr Cardiol Rep       Date:  2019-08-03       Impact factor: 2.931

5.  Speckle-tracking and tissue-Doppler stress echocardiography in arterial hypertension: a sensitive tool for detection of subclinical LV impairment.

Authors:  Kai O Hensel; Andreas Jenke; Roman Leischik
Journal:  Biomed Res Int       Date:  2014-10-15       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.